Skip to main content

Advertisement

SpringerLink
Log in

Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System

  • Expert Review
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Major central nervous system (CNS) disorders, including brain tumors, Alzheimer’s disease, Parkinson’s disease, and stroke, are significant threats to human health. Although impressive advances in the treatment of CNS disorders have been made during the past few decades, the success rates are still moderate if not poor. The blood–brain barrier (BBB) hampers the access of systemically administered drugs to the brain. The development of nanotechnology provides powerful tools to deliver therapeutics to target sites. Anchoring them with specific ligands can endow the nano-therapeutics with the appropriate properties to circumvent the BBB. In this review, the potential nanotechnology-based targeted drug delivery strategies for different CNS disorders are described. The limitations and future directions of brain-targeted delivery systems are also discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

REFERENCES

  1. Wohlfart S, Gelperinaand S, Kreuter J. Transport of drugs across the blood–brain barrier by nanoparticles. J Control Release. 2012;161:264–73.

    Google Scholar 

  2. Begley DJ. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities. Pharmacol Ther. 2004;104:29–45.

    Article  PubMed  CAS  Google Scholar 

  3. Brasnjevic I, Steinbusch HW, Schmitz C, Martinez-Martinez P. Delivery of peptide and protein drugs over the blood–brain barrier. Prog Neurobiol. 2009;87:212–51.

    Article  PubMed  CAS  Google Scholar 

  4. Pardridge WM. CNS drug design based on principles of blood–brain barrier transport. J Neurochem. 1998;70:1781–92.

    Article  PubMed  CAS  Google Scholar 

  5. Pardridge WM. Drug targeting to the brain. Pharm Res. 2007;24:1733–44.

    Article  PubMed  CAS  Google Scholar 

  6. Guo L, Renand J, Jiang X. Perspectives on brain-targeting drug delivery systems. Curr Pharm Biotechnol. 2012;13:2310–8.

    Article  PubMed  CAS  Google Scholar 

  7. Srikanthand M, Kessler JA. Nanotechnology-novel therapeutics for CNS disorders. Nat Rev Neurol. 2012;8:307–18.

    Article  CAS  Google Scholar 

  8. Liuand Y, Lu W. Recent advances in brain tumor-targeted nano-drug delivery systems. Expert Opin Drug Deliv. 2012;9:671–86.

    Article  CAS  Google Scholar 

  9. Ricard D, Idbaih A, Ducray F, Lahutte M, Hoang-Xuan K, Delattre JY. Primary brain tumours in adults. Lancet. 2012;379:1984–96.

    Article  PubMed  Google Scholar 

  10. Allhenn D, Boushehriand MA, Lamprecht A. Drug delivery strategies for the treatment of malignant gliomas. Int J Pharm. 2012;436:299–310.

    Article  PubMed  CAS  Google Scholar 

  11. Agarwal S, Sane R, Oberoi R, Ohlfest JR, Elmquist WF. Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Rev Mol Med. 2011;13:e17.

    Article  PubMed  CAS  Google Scholar 

  12. Bidrosand DS, Vogelbaum MA. Novel drug delivery strategies in neuro-oncology. Neurotherapeutics. 2009;6:539–46.

    Article  Google Scholar 

  13. Clarke J, Butowskiand N, Chang S. Recent advances in therapy for glioblastoma. Arch Neurol. 2010;67:279–83.

    Article  PubMed  Google Scholar 

  14. Wolburg H, Noell S, Fallier-Becker P, Mack AF, Wolburg-Buchholz K. The disturbed blood–brain barrier in human glioblastoma. Mol Aspects Med. 2012;33:579–89.

    Article  PubMed  CAS  Google Scholar 

  15. Agarwal S, Manchanda P, Vogelbaum MA, Ohlfest JR, Elmquist WF. Function of the blood–brain barrier and restriction of drug delivery to invasive glioma cells: findings in an orthotopic rat xenograft model of glioma. Drug Metab Dispos. 2013;41:33–9.

    Article  PubMed  CAS  Google Scholar 

  16. Bronger H, Konig J, Kopplow K, Steiner HH, Ahmadi R, Herold-Mende C, et al. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res. 2005;65:11419–28.

    Article  PubMed  CAS  Google Scholar 

  17. Groothuis DR. The blood–brain and blood-tumor barriers: a review of strategies for increasing drug delivery. Neuro Oncol. 2000;2:45–59.

    PubMed  CAS  Google Scholar 

  18. Roberts WG, Delaat J, Nagane M, Huang S, Cavenee WK, Palade GE. Host microvasculature influence on tumor vascular morphology and endothelial gene expression. Am J Pathol. 1998;153:1239–48.

    Article  PubMed  CAS  Google Scholar 

  19. Zhanand C, Lu W. The blood–brain/tumor barriers: challenges and chances for malignant gliomas targeted drug delivery. Curr Pharm Biotechnol. 2012;13:2380–7.

    Article  Google Scholar 

  20. Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95:4607–12.

    Article  PubMed  CAS  Google Scholar 

  21. Sarin H, Kanevsky AS, Wu H, Sousa AA, Wilson CM, Aronova MA, et al. Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med. 2009;7:51.

    Article  PubMed  Google Scholar 

  22. Sarin H, Kanevsky AS, Wu H, Brimacombe KR, Fung SH, Sousa AA, et al. Effective transvascular delivery of nanoparticles across the blood–brain tumor barrier into malignant glioma cells. J Transl Med. 2008;6:80.

    Article  PubMed  CAS  Google Scholar 

  23. Mohri M, Nittaand H, Yamashita J. Expression of multidrug resistance-associated protein (MRP) in human gliomas. J Neurooncol. 2000;49:105–15.

    Article  PubMed  CAS  Google Scholar 

  24. Fattori S, Becherini F, Cianfriglia M, Parenti G, Romanini A, Castagna M. Human brain tumors: multidrug-resistance P-glycoprotein expression in tumor cells and intratumoral capillary endothelial cells. Virchows Arch. 2007;451:81–7.

    Article  PubMed  CAS  Google Scholar 

  25. Taskar KS, Rudraraju V, Mittapalli RK, Samala R, Thorsheim HR, Lockman J, et al. Lapatinib distribution in HER2 overexpressing experimental brain metastases of breast cancer. Pharm Res. 2012;29:770–81.

    Article  PubMed  CAS  Google Scholar 

  26. Pang Z, Gao H, Yu Y, Guo L, Chen J, Pan S, et al. Enhanced intracellular delivery and chemotherapy for glioma rats by transferrin-conjugated biodegradable polymersomes loaded with Doxorubicin. Bioconjug Chem. 2011;22:1171–80.

    Article  PubMed  CAS  Google Scholar 

  27. Pang Z, Lu W, Gao H, Hu K, Chen J, Zhang C, et al. Preparation and brain delivery property of biodegradable polymersomes conjugated with OX26. J Control Release. 2008;128:120–7.

    Article  PubMed  CAS  Google Scholar 

  28. Zhan C, Li B, Hu L, Wei X, Feng L, Fu W, et al. Micelle-based brain-targeted drug delivery enabled by a nicotine acetylcholine receptor ligand. Angew Chem Int Ed Engl. 2011;50:5482–5.

    Article  PubMed  CAS  Google Scholar 

  29. Gaillard PJ, Visser CC, Appeldoorn CCM, Rip J. Enhanced brain drug delivery: safely crossing the blood–brain barrier. Drug Discov Today Technol. 2012;9:e155–60.

    Article  CAS  Google Scholar 

  30. Lu W, Wan J, Zhang Q, She Z, Jiang X. Aclarubicin-loaded cationic albumin-conjugated pegylated nanoparticle for glioma chemotherapy in rats. Int J Cancer. 2007;120:420–31.

    Article  PubMed  CAS  Google Scholar 

  31. Lu W, Sun Q, Wan J, She Z, Jiang XG. Cationic albumin-conjugated pegylated nanoparticles allow gene delivery into brain tumors via intravenous administration. Cancer Res. 2006;66:11878–87.

    Article  PubMed  CAS  Google Scholar 

  32. Gao H, Pang Z, Pan S, Cao S, Yang Z, Chen C, et al. Anti-glioma effect and safety of docetaxel-loaded nanoemulsion. Arch Pharm Res. 2012;35:333–41.

    Article  CAS  Google Scholar 

  33. Hovanessian AG, Soundaramourty C, El KD, Nondier I, Svab J, Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One. 2010;5:e15787.

    Article  PubMed  CAS  Google Scholar 

  34. Maletinska L, Blakely EA, Bjornstad KA, Deen DF, Knoff LJ, Forte TM. Human glioblastoma cell lines: levels of low-density lipoprotein receptor and low-density lipoprotein receptor-related protein. Cancer Res. 2000;60:2300–3.

    PubMed  CAS  Google Scholar 

  35. Zhang YF, Wang JC, Bian DY, Zhang X, Zhang Q. Targeted delivery of RGD-modified liposomes encapsulating both combretastatin A-4 and doxorubicin for tumor therapy: in vitro and in vivo studies. Eur J Pharm Biopharm. 2010;74:467–73.

    Article  PubMed  CAS  Google Scholar 

  36. Huang R, Ke W, Han L, Li J, Liu S, Jiang C. Targeted delivery of chlorotoxin-modified DNA-loaded nanoparticles to glioma via intravenous administration. Biomaterials. 2011;32:2399–406.

    Article  PubMed  CAS  Google Scholar 

  37. Mamot C, Drummond DC, Noble CO, Kallab V, Guo Z, Hong K, et al. Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. 2005;65:11631–8.

    Article  PubMed  CAS  Google Scholar 

  38. Iresonand CR, Kelland LR. Discovery and development of anticancer aptamers. Mol Cancer Ther. 2006;5:2957–62.

    Article  CAS  Google Scholar 

  39. Guo J, Gao X, Su L, Xia H, Gu G, Pang Z, et al. Aptamer-functionalized PEG-PLGA nanoparticles for enhanced anti-glioma drug delivery. Biomaterials. 2011;32:8010–20.

    Article  PubMed  CAS  Google Scholar 

  40. Gao H, Qian J, Yang Z, Pang Z, Xi Z, Cao S, et al. Whole-cell SELEX aptamer-functionalised poly(ethyleneglycol)-poly(epsilon-caprolactone) nanoparticles for enhanced targeted glioblastoma therapy. Biomaterials. 2012;33:6264–72.

    Article  PubMed  CAS  Google Scholar 

  41. Gu G, Xia H, Hu Q, Liu Z, Jiang M, Kang T, et al. PEG-co-PCL nanoparticles modified with MMP-2/9 activatable low molecular weight protamine for enhanced targeted glioblastoma therapy. Biomaterials. 2013;34:196–208.

    Article  PubMed  CAS  Google Scholar 

  42. Jiang T, Olson ES, Nguyen QT, Roy M, Jennings PA, Tsien RY. Tumor imaging by means of proteolytic activation of cell-penetrating peptides. Proc Natl Acad Sci U S A. 2004;101:17867–72.

    Article  PubMed  CAS  Google Scholar 

  43. Kuai R, Yuan W, Li W, Qin Y, Tang J, Yuan M, et al. Targeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administration. Mol Pharm. 2011;8:2151–61.

    Article  PubMed  CAS  Google Scholar 

  44. Kuai R, Yuan W, Qin Y, Chen H, Tang J, Yuan M, et al. Efficient delivery of payload into tumor cells in a controlled manner by TAT and thiolytic cleavable PEG co-modified liposomes. Mol Pharm. 2010;7:1816–26.

    Google Scholar 

  45. Sawant RM, Hurley JP, Salmaso S, Kale A, Tolcheva E, Levchenko TS, et al. “SMART” drug delivery systems: double-targeted pH-responsive pharmaceutical nanocarriers. Bioconjug Chem. 2006;17:943–9.

    Article  PubMed  CAS  Google Scholar 

  46. Xu H, Deng Y, Chen D, Hong W, Lu Y, Dong X. Esterase-catalyzed dePEGylation of pH-sensitive vesicles modified with cleavable PEG-lipid derivatives. J Control Release. 2008;130:238–45.

    Article  PubMed  CAS  Google Scholar 

  47. Guo L, Fan L, Pang Z, Ren J, Ren Y, Li J, et al. TRAIL and doxorubicin combination enhances anti-glioblastoma effect based on passive tumor targeting of liposomes. J Control Release. 2011;154:93–102.

    Article  PubMed  CAS  Google Scholar 

  48. Zhan C, Wei X, Qian J, Feng L, Zhu J, Lu W. Co-delivery of TRAIL gene enhances the anti-glioblastoma effect of paclitaxel in vitro and in vivo. J Control Release. 2012;160:630–6.

    Article  PubMed  CAS  Google Scholar 

  49. Schottelius M, Laufer B, Kessler H, Wester HJ. Ligands for mapping alphavbeta3-integrin expression in vivo. Acc Chem Res. 2009;42:969–80.

    Article  PubMed  CAS  Google Scholar 

  50. Sun X, Pang Z, Ye H, Qiu B, Guo L, Li J, et al. Co-delivery of pEGFP-hTRAIL and paclitaxel to brain glioma mediated by an angiopep-conjugated liposome. Biomaterials. 2012;33:916–24.

    PubMed  CAS  Google Scholar 

  51. Li J, Feng L, Fan L, Zha Y, Guo L, Zhang Q, et al. Targeting the brain with PEG-PLGA nanoparticles modified with phage-displayed peptides. Biomaterials. 2011;32:4943–50.

    Article  PubMed  CAS  Google Scholar 

  52. Gao H, Qian J, Cao S, Yang Z, Pang Z, Pan S, et al. Precise glioma targeting of and penetration by aptamer and peptide dual-functioned nanoparticles. Biomaterials. 2012;33:5115–23.

    Article  PubMed  CAS  Google Scholar 

  53. Xu Q, Liu Y, Su S, Li W, Chen C, Wu Y. Anti-tumor activity of paclitaxel through dual-targeting carrier of cyclic RGD and transferrin conjugated hyperbranched copolymer nanoparticles. Biomaterials. 2012;33:1627–39.

    Article  PubMed  CAS  Google Scholar 

  54. Li Y, He H, Jia X, Lu WL, Lou J, Wei Y. A dual-targeting nanocarrier based on poly(amidoamine) dendrimers conjugated with transferrin and tamoxifen for treating brain gliomas. Biomaterials. 2012;33:3899–908.

    Article  PubMed  CAS  Google Scholar 

  55. Zhang P, Hu L, Yin Q, Feng L, Li Y. Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood–brain barrier penetration and glioma targeting therapy. Mol Pharm. 2012;9:1590–8.

    Article  PubMed  CAS  Google Scholar 

  56. Nie Y, Schaffert D, Rodl W, Ogris M, Wagner E, Gunther M. Dual-targeted polyplexes: one step towards a synthetic virus for cancer gene therapy. J Control Release. 2011;152:127–34.

    Article  PubMed  CAS  Google Scholar 

  57. Ying X, Wen H, Lu WL, Du J, Guo J, Tian W, et al. Dual-targeting daunorubicin liposomes improve the therapeutic efficacy of brain glioma in animals. J Control Release. 2010;141:183–92.

    Article  PubMed  CAS  Google Scholar 

  58. He H, Li Y, Jia XR, Du J, Ying X, Lu WL, et al. PEGylated Poly(amidoamine) dendrimer-based dual-targeting carrier for treating brain tumors. Biomaterials. 2011;32:478–87.

    Article  PubMed  CAS  Google Scholar 

  59. Du J, Lu WL, Ying X, Liu Y, Du P, Tian W, et al. Dual-targeting topotecan liposomes modified with tamoxifen and wheat germ agglutinin significantly improve drug transport across the blood–brain barrier and survival of brain tumor-bearing animals. Mol Pharm. 2009;6:905–17.

    Article  PubMed  CAS  Google Scholar 

  60. Kakimoto S, Moriyama T, Tanabe T, Shinkai S, Nagasaki T. Dual-ligand effect of transferrin and transforming growth factor alpha on polyethyleneimine-mediated gene delivery. J Control Release. 2007;120:242–9.

    Article  PubMed  CAS  Google Scholar 

  61. Ito S, Ohtsukiand S, Terasaki T. Functional characterization of the brain-to-blood efflux clearance of human amyloid-beta peptide (1–40) across the rat blood–brain barrier. Neurosci Res. 2006;56:246–52.

    Article  PubMed  CAS  Google Scholar 

  62. Liand H, Qian ZM. Transferrin/transferrin receptor-mediated drug delivery. Med Res Rev. 2002;22:225–50.

    Article  CAS  Google Scholar 

  63. Demeule M, Regina A, Che C, Poirier J, Nguyen T, Gabathuler R, et al. Identification and design of peptides as a new drug delivery system for the brain. J Pharmacol Exp Ther. 2008;324:1064–72.

    Article  PubMed  CAS  Google Scholar 

  64. Ke W, Shao K, Huang R, Han L, Liu Y, Li J, et al. Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer. Biomaterials. 2009;30:6976–85.

    Article  PubMed  CAS  Google Scholar 

  65. Xin H, Sha X, Jiang X, Zhang W, Chen L, Fang X. Anti-glioblastoma efficacy and safety of paclitaxel-loading Angiopep-conjugated dual targeting PEG-PCL nanoparticles. Biomaterials. 2012;33:8167–76.

    Google Scholar 

  66. Re F, Gregoriand M, Masserini M. Nanotechnology for neurodegenerative disorders. Nanomedicine. 2012;8 Suppl 1:S51–8.

    PubMed  CAS  Google Scholar 

  67. Tanifum EA, Dasgupta I, Srivastava M, Bhavane RC, Sun L, Berridge J, et al. Intravenous delivery of targeted liposomes to amyloid-beta pathology in APP/PSEN1 transgenic mice. PLoS One. 2012;7:e48515.

    Article  PubMed  CAS  Google Scholar 

  68. Tanziand RE, Bertram L. Twenty years of the Alzheimer’s disease amyloid hypothesis: a genetic perspective. Cell. 2005;120:545–55.

    Article  CAS  Google Scholar 

  69. Santacruz K, Lewis J, Spires T, Paulson J, Kotilinek L, Ingelsson M, et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science. 2005;309:476–81.

    Article  PubMed  CAS  Google Scholar 

  70. Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, et al. Anti-Abeta antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005;115:428–33.

    PubMed  CAS  Google Scholar 

  71. Zhou QH, Fu A, Boado RJ, Hui EK, Lu JZ, Pardridge WM. Receptor-mediated abeta amyloid antibody targeting to Alzheimer’s disease mouse brain. Mol Pharm. 2011;8:280–5.

    Article  PubMed  CAS  Google Scholar 

  72. Chauhan NB, Davisand F, Xiao C. Wheat germ agglutinin enhanced cerebral uptake of anti-Abeta antibody after intranasal administration in 5XFAD mice. Vaccine. 2011;29:7631–7.

    Article  PubMed  CAS  Google Scholar 

  73. Ono K, Hasegawa K, Naiki H, Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer’s beta-amyloid fibrils in vitro. J Neurosci Res. 2004;75:742–50.

    Article  PubMed  CAS  Google Scholar 

  74. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Ambegaokar SS, et al. Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J Biol Chem. 2005;280:5892–901.

    Article  PubMed  CAS  Google Scholar 

  75. Mourtas S, Canovi M, Zona C, Aurilia D, Niarakis A, La Ferla B, et al. Curcumin-decorated nanoliposomes with very high affinity for amyloid-beta1-42 peptide. Biomaterials. 2011;32:1635–45.

    Article  PubMed  CAS  Google Scholar 

  76. Mathew A, Fukuda T, Nagaoka Y, Hasumura T, Morimoto H, Yoshida Y, et al. Curcumin loaded-PLGA nanoparticles conjugated with Tet-1 peptide for potential use in Alzheimer’s disease. PLoS One. 2012;7:e32616.

    Article  PubMed  CAS  Google Scholar 

  77. Taylor M, Moore S, Mourtas S, Niarakis A, Re F, Zona C, et al. Effect of curcumin-associated and lipid ligand-functionalized nanoliposomes on aggregation of the Alzheimer’s Abeta peptide. Nanomedicine. 2011;7:541–50.

    Article  PubMed  CAS  Google Scholar 

  78. Mulik RS, Monkkonen J, Juvonen RO, Mahadik KR, Paradkar AR. ApoE3 mediated poly(butyl) cyanoacrylate nanoparticles containing curcumin: study of enhanced activity of curcumin against beta amyloid induced cytotoxicity using in vitro cell culture model. Mol Pharm. 2010;7:815–25.

    Article  PubMed  CAS  Google Scholar 

  79. Liu JK, Teng Q, Garrity-Moses M, Federici T, Tanase D, Imperiale MJ, et al. A novel peptide defined through phage display for therapeutic protein and vector neuronal targeting. Neurobiol Dis. 2005;19:407–18.

    Article  PubMed  CAS  Google Scholar 

  80. Brambilla D, Le Droumaguet B, Nicolas J, Hashemi SH, Wu LP, Moghimi SM, et al. Nanotechnologies for Alzheimer’s disease: diagnosis, therapy, and safety issues. Nanomedicine. 2011;7:521–40.

    Article  PubMed  CAS  Google Scholar 

  81. Cui Z, Lockman PR, Atwood CS, Hsu CH, Gupte A, Allen DD, et al. Novel D-penicillamine carrying nanoparticles for metal chelation therapy in Alzheimer’s and other CNS diseases. Eur J Pharm Biopharm. 2005;59:263–72.

    Article  PubMed  CAS  Google Scholar 

  82. Yang Z, Zhang Y, Yang Y, Sun L, Han D, Li H, et al. Pharmacological and toxicological target organelles and safe use of single-walled carbon nanotubes as drug carriers in treating Alzheimer disease. Nanomedicine. 2010;6:427–41.

    Article  PubMed  CAS  Google Scholar 

  83. Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2001;47:65–81.

    Article  PubMed  CAS  Google Scholar 

  84. Wilson B, Samanta MK, Santhi K, Kumar KP, Paramakrishnan N, Suresh B. Poly(n-butylcyanoacrylate) nanoparticles coated with polysorbate 80 for the targeted delivery of rivastigmine into the brain to treat Alzheimer’s disease. Brain Res. 2008;1200:159–68.

    Article  PubMed  CAS  Google Scholar 

  85. Joshi SA, Chavhanand SS, Sawant KK. Rivastigmine-loaded PLGA and PBCA nanoparticles: preparation, optimization, characterization, in vitro and pharmacodynamic studies. Eur J Pharm Biopharm. 2010;76:189–99.

    Article  PubMed  CAS  Google Scholar 

  86. Mamiyaand T, Ukai M. [Gly(14)]-Humanin improved the learning and memory impairment induced by scopolamine in vivo. Br J Pharmacol. 2001;134:1597–9.

    Article  Google Scholar 

  87. Yu Y, Pang Z, Lu W, Yin Q, Gao H, Jiang X. Self-assembled polymersomes conjugated with lactoferrin as novel drug carrier for brain delivery. Pharm Res. 2012;29:83–96.

    Article  PubMed  CAS  Google Scholar 

  88. Li J, Zhang C, Li J, Fan L, Jiang X, Chen J, et al. Brain delivery of NAP with PEG-PLGA nanoparticles modified with phage display peptides. Pharm Res. 2013;30:1813–23.

    Google Scholar 

  89. Mishima K, Tsukikawa H, Miura I, Inada K, Abe K, Matsumoto Y, et al. Ameliorative effect of NC-1900, a new AVP4-9 analog, through vasopressin V1A receptor on scopolamine-induced impairments of spatial memory in the eight-arm radial maze. Neuropharmacology. 2003;44:541–52.

    Article  PubMed  CAS  Google Scholar 

  90. Wu H, Huand K, Jiang X. From nose to brain: understanding transport capacity and transport rate of drugs. Expert Opin Drug Deliv. 2008;5:1159–68.

    Article  PubMed  CAS  Google Scholar 

  91. Gao X, Wu B, Zhang Q, Chen J, Zhu J, Zhang W, et al. Brain delivery of vasoactive intestinal peptide enhanced with the nanoparticles conjugated with wheat germ agglutinin following intranasal administration. J Control Release. 2007;121:156–67.

    Article  PubMed  CAS  Google Scholar 

  92. Gao X, Tao W, Lu W, Zhang Q, Zhang Y, Jiang X, et al. Lectin-conjugated PEG-PLA nanoparticles: preparation and brain delivery after intranasal administration. Biomaterials. 2006;27:3482–90.

    Article  PubMed  CAS  Google Scholar 

  93. Li J, Wu H, Hong J, Xu X, Yang H, Wu B, et al. Odorranalectin is a small peptide lectin with potential for drug delivery and targeting. PLoS One. 2008;3:e2381.

    Article  PubMed  CAS  Google Scholar 

  94. Wu H, Li J, Zhang Q, Yan X, Guo L, Gao X, et al. A novel small Odorranalectin-bearing cubosomes: preparation, brain delivery and pharmacodynamic study on amyloid-beta(2)(5)(−)(3)(5)-treated rats following intranasal administration. Eur J Pharm Biopharm. 2012;80:368–78.

    Article  PubMed  CAS  Google Scholar 

  95. Denyerand R, Douglas MR. Gene therapy for Parkinson’s disease. Parkinsons Dis. 2012;2012:757305.

    Google Scholar 

  96. Macpheeand GJ, Carson A. Impulse control disorders in Parkinson disease: is cognitive-behavioral therapy worth a wager? Neurology. 2013;80:782–3.

    Article  Google Scholar 

  97. Reddy P, Martinez-Martin P, Rizos A, Martin A, Faye GC, Forgacs I, et al. Intrajejunal levodopa versus conventional therapy in Parkinson disease: motor and nonmotor effects. Clin Neuropharmacol. 2012;35:205–7.

    Article  PubMed  CAS  Google Scholar 

  98. Soler R, Fullhase C, Hanson A, Campeau L, Santos C, Andersson KE. Stem cell therapy ameliorates bladder dysfunction in an animal model of Parkinson disease. J Urol. 2012;187:1491–7.

    Article  PubMed  Google Scholar 

  99. Alonso-Frech F, Sanahujaand JJ, Rodriguez AM. Exercise and physical therapy in early management of Parkinson disease. Neurologist. 2011;17:S47–53.

    Article  PubMed  Google Scholar 

  100. Ronand D, Janak PH. GDNF and addiction. Rev Neurosci. 2005;16:277–85.

    Google Scholar 

  101. Zhou QH, Boado RJ, Lu JZ, Hui EK, Pardridge WM. Monoclonal antibody-glial-derived neurotrophic factor fusion protein penetrates the blood–brain barrier in the mouse. Drug Metab Dispos. 2010;38:566–72.

    Article  PubMed  CAS  Google Scholar 

  102. Abuirmeileh A, Lever R, Kingsbury AE, Lees AJ, Locke IC, Knight RA, et al. The corticotrophin-releasing factor-like peptide urocortin reverses key deficits in two rodent models of Parkinson’s disease. Eur J Neurosci. 2007;26:417–23.

    Article  PubMed  Google Scholar 

  103. Hu K, Li J, Shen Y, Lu W, Gao X, Zhang Q, et al. Lactoferrin-conjugated PEG-PLA nanoparticles with improved brain delivery: in vitro and in vivo evaluations. J Control Release. 2009;134:55–61.

    Article  PubMed  CAS  Google Scholar 

  104. Hu K, Shi Y, Jiang W, Han J, Huang S, Jiang X. Lactoferrin conjugated PEG-PLGA nanoparticles for brain delivery: preparation, characterization and efficacy in Parkinson’s disease. Int J Pharm. 2011;415:273–83.

    Article  PubMed  CAS  Google Scholar 

  105. Wen Z, Yan Z, Hu K, Pang Z, Cheng X, Guo L, et al. Odorranalectin-conjugated nanoparticles: preparation, brain delivery and pharmacodynamic study on Parkinson’s disease following intranasal administration. J Control Release. 2011;151:131–8.

    Article  PubMed  CAS  Google Scholar 

  106. Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther. 2003;14:1–12.

    Article  PubMed  Google Scholar 

  107. Gonzalez-Barrios JA, Lindahl M, Bannon MJ, Anaya-Martinez V, Flores G, Navarro-Quiroga I, et al. Neurotensin polyplex as an efficient carrier for delivering the human GDNF gene into nigral dopamine neurons of hemiparkinsonian rats. Mol Ther. 2006;14:857–65.

    Article  PubMed  CAS  Google Scholar 

  108. Martinez-Fong D, Bannon MJ, Trudeau LE, Gonzalez-Barrios JA, Arango-Rodriguez ML, Hernandez-Chan NG, et al. NTS-Polyplex: a potential nanocarrier for neurotrophic therapy of Parkinson’s disease. Nanomedicine. 2012;8:1052–69.

    Article  PubMed  CAS  Google Scholar 

  109. Huang R, Ke W, Liu Y, Jiang C, Pei Y. The use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brain. Biomaterials. 2008;29:238–46.

    Article  PubMed  CAS  Google Scholar 

  110. Huang R, Han L, Li J, Ren F, Ke W, Jiang C, et al. Neuroprotection in a 6-hydroxydopamine-lesioned Parkinson model using lactoferrin-modified nanoparticles. J Gene Med. 2009;11:754–63.

    Article  PubMed  CAS  Google Scholar 

  111. Huang J, Liu H, Gu W, Yan Z, Xu Z, Yang Y, et al. A delivery strategy for rotenone microspheres in an animal model of Parkinson’s disease. Biomaterials. 2006;27:937–46.

    Article  PubMed  CAS  Google Scholar 

  112. Sindhu KM, Saravananand KS, Mohanakumar KP. Behavioral differences in a rotenone-induced hemiparkinsonian rat model developed following intranigral or median forebrain bundle infusion. Brain Res. 2005;1051:25–34.

    Article  PubMed  CAS  Google Scholar 

  113. Huang R, Ke W, Liu Y, Wu D, Feng L, Jiang C, et al. Gene therapy using lactoferrin-modified nanoparticles in a rotenone-induced chronic Parkinson model. J Neurol Sci. 2010;290:123–30.

    Article  PubMed  CAS  Google Scholar 

  114. Andersonand JT, Robertson NP. Risk factors and cerebrovascular disease. J Neurol. 2013;260:692–4.

    Article  Google Scholar 

  115. Cooke MJ, Wang Y, Morshead CM, Shoichet MS. Controlled epi-cortical delivery of epidermal growth factor for the stimulation of endogenous neural stem cell proliferation in stroke-injured brain. Biomaterials. 2011;32:5688–97.

    Article  PubMed  CAS  Google Scholar 

  116. Gupta A, Nair S, Schweitzer AD, Kishore S, Johnson CE, Comunale JP, et al. Neuroimaging of cerebrovascular disease in the aging brain. Aging Dis. 2012;3:414–25.

    PubMed  Google Scholar 

  117. Elger B, Gieseler M, Schmuecker O, Schumann I, Seltz A, Huth A. Extended therapeutic time window after focal cerebral ischemia by non-competitive inhibition of AMPA receptors. Brain Res. 2006;1085:189–94.

    Article  PubMed  CAS  Google Scholar 

  118. Wuand D, Pardridge WM. Neuroprotection with noninvasive neurotrophin delivery to the brain. Proc Natl Acad Sci U S A. 1999;96:254–9.

    Article  Google Scholar 

  119. Zhangand Y, Pardridge WM. Conjugation of brain-derived neurotrophic factor to a blood–brain barrier drug targeting system enables neuroprotection in regional brain ischemia following intravenous injection of the neurotrophin. Brain Res. 2001;889:49–56.

    Article  Google Scholar 

  120. Pardridge WM. Blood–brain barrier drug targeting enables neuroprotection in brain ischemia following delayed intravenous administration of neurotrophins. Adv Exp Med Biol. 2002;513:397–430.

    Article  PubMed  CAS  Google Scholar 

  121. Wu D. Neuroprotection in experimental stroke with targeted neurotrophins. NeuroRx. 2005;2:120–8.

    Article  PubMed  Google Scholar 

  122. Song BW, Vinters HV, Wu D, Pardridge WM. Enhanced neuroprotective effects of basic fibroblast growth factor in regional brain ischemia after conjugation to a blood–brain barrier delivery vector. J Pharmacol Exp Ther. 2002;301:605–10.

    Article  PubMed  CAS  Google Scholar 

  123. D’Agnilloand F, Alayash AI. Site-specific modifications and toxicity of blood substitutes. The case of diaspirin cross-linked hemoglobin. Adv Drug Deliv Rev. 2000;40:199–212.

    Article  Google Scholar 

  124. Conover CD, Linberg R, Shum KL, Shorr RG. The ability of polyethylene glycol conjugated bovine hemoglobin (PEG-Hb) to adequately deliver oxygen in both exchange transfusion and top-loaded rat models. Artif Cells Blood Substit Immobil Biotechnol. 1999;27:93–107.

    Article  PubMed  CAS  Google Scholar 

  125. Lee J, Lee J, Yoon S, Nho K. Pharmacokinetics of 125I-radiolabelled PEG-hemoglobin SB1. Artif Cells Blood Substit Immobil Biotechnol. 2006;34:277–92.

    Article  PubMed  CAS  Google Scholar 

  126. Ji HJ, Chai HY, Nahm SS, Lee J, Bae GW, Nho K, et al. Neuroprotective effects of the novel polyethylene glycol-hemoglobin conjugate SB1 on experimental cerebral thromboembolism in rats. Eur J Pharmacol. 2007;566:83–7.

    Article  PubMed  CAS  Google Scholar 

  127. Reddyand MK, Labhasetwar V. Nanoparticle-mediated delivery of superoxide dismutase to the brain: an effective strategy to reduce ischemia-reperfusion injury. FASEB J. 2009;23:1384–95.

    Article  CAS  Google Scholar 

  128. Erlandsson A, Lin CH, Yu F, Morshead CM. Immunosuppression promotes endogenous neural stem and progenitor cell migration and tissue regeneration after ischemic injury. Exp Neurol. 2011;230:48–57.

    Article  PubMed  CAS  Google Scholar 

  129. Kolb B, Morshead C, Gonzalez C, Kim M, Gregg C, Shingo T, et al. Growth factor-stimulated generation of new cortical tissue and functional recovery after stroke damage to the motor cortex of rats. J Cereb Blood Flow Metab. 2007;27:983–97.

    PubMed  CAS  Google Scholar 

  130. Wang Y, Cooke MJ, Lapitsky Y, Wylie RG, Sachewsky N, Corbett D, et al. Transport of epidermal growth factor in the stroke-injured brain. J Control Release. 2011;149:225–35.

    Article  PubMed  CAS  Google Scholar 

  131. Wang Y, Cooke MJ, Morshead CM, Shoichet MS. Hydrogel delivery of erythropoietin to the brain for endogenous stem cell stimulation after stroke injury. Biomaterials. 2012;33:2681–92.

    Article  PubMed  CAS  Google Scholar 

  132. Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest. 2003;111:1843–51.

    PubMed  CAS  Google Scholar 

  133. Zhao H, Bao XJ, Wang RZ, Li GL, Gao J, Ma SH, et al. Postacute ischemia vascular endothelial growth factor transfer by transferrin-targeted liposomes attenuates ischemic brain injury after experimental stroke in rats. Hum Gene Ther. 2011;22:207–15.

    Article  PubMed  CAS  Google Scholar 

  134. Kim JB, Sig CJ, Yu YM, Nam K, Piao CS, Kim SW, et al. HMGB1, a novel cytokine-like mediator linking acute neuronal death and delayed neuroinflammation in the postischemic brain. J Neurosci. 2006;26:6413–21.

    Article  PubMed  CAS  Google Scholar 

  135. Kim ID, Lim CM, Kim JB, Nam HY, Nam K, Kim SW, et al. Neuroprotection by biodegradable PAMAM ester (e-PAM-R)-mediated HMGB1 siRNA delivery in primary cortical cultures and in the postischemic brain. J Control Release. 2010;142:422–30.

    Article  PubMed  CAS  Google Scholar 

  136. Budihardjo I, Oliver H, Lutter M, Luo X, Wang X. Biochemical pathways of caspase activation during apoptosis. Annu Rev Cell Dev Biol. 1999;15:269–90.

    Article  PubMed  CAS  Google Scholar 

  137. Al-Jamal KT, Gherardini L, Bardi G, Nunes A, Guo C, Bussy C, et al. Functional motor recovery from brain ischemic insult by carbon nanotube-mediated siRNA silencing. Proc Natl Acad Sci U S A. 2011;108:10952–7.

    Article  PubMed  CAS  Google Scholar 

  138. Lee J, Hyun H, Kim J, Ryu JH, Kim HA, Park JH, et al. Dexamethasone-loaded peptide micelles for delivery of the heme oxygenase-1 gene to ischemic brain. J Control Release. 2012;158:131–8.

    Article  PubMed  CAS  Google Scholar 

  139. Yu YP, Xu QQ, Zhang Q, Zhang WP, Zhang LH, Wei EQ. Intranasal recombinant human erythropoietin protects rats against focal cerebral ischemia. Neurosci Lett. 2005;387:5–10.

    Article  PubMed  CAS  Google Scholar 

  140. Wang ZL, Cheng SM, Ma MM, Ma YP, Yang JP, Xu GL, et al. Intranasally delivered bFGF enhances neurogenesis in adult rats following cerebral ischemia. Neurosci Lett. 2008;446:30–5.

    Article  PubMed  CAS  Google Scholar 

  141. Hanson LR, Roeytenberg A, Martinez PM, Coppes VG, Sweet DC, Rao RJ, et al. Intranasal deferoxamine provides increased brain exposure and significant protection in rat ischemic stroke. J Pharmacol Exp Ther. 2009;330:679–86.

    Article  PubMed  CAS  Google Scholar 

  142. Jiang Y, Wei N, Lu T, Zhu J, Xu G, Liu X. Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience. 2011;172:398–405.

    Article  PubMed  CAS  Google Scholar 

  143. Cheng X, Wang Z, Yang J, Ma M, Lu T, Xu G, et al. Acidic fibroblast growth factor delivered intranasally induces neurogenesis and angiogenesis in rats after ischemic stroke. Neurol Res. 2011;33:675–80.

    Article  PubMed  CAS  Google Scholar 

  144. Lu T, Jiang Y, Zhou Z, Yue X, Wei N, Chen Z, et al. Intranasal ginsenoside Rb1 targets the brain and ameliorates cerebral ischemia/reperfusion injury in rats. Biol Pharm Bull. 2011;34:1319–24.

    Article  PubMed  CAS  Google Scholar 

  145. Kim ID, Shin JH, Lee HK, Jin YC, Lee JK. Intranasal delivery of HMGB1-binding heptamer peptide confers a robust neuroprotection in the postischemic brain. Neurosci Lett. 2012;525:179–83.

    Article  PubMed  CAS  Google Scholar 

  146. Zhu J, Jiang Y, Wu L, Lu T, Xu G, Liu X. Suppression of local inflammation contributes to the neuroprotective effect of ginsenoside Rb1 in rats with cerebral ischemia. Neuroscience. 2012;202:342–51.

    Article  PubMed  CAS  Google Scholar 

  147. Kim ID, Shin JH, Kim SW, Choi S, Ahn J, Han PL, et al. Intranasal delivery of HMGB1 siRNA confers target gene knockdown and robust neuroprotection in the postischemic brain. Mol Ther. 2012;20:829–39.

    Article  PubMed  CAS  Google Scholar 

  148. Liu L, Venkatraman SS, Yang YY, Guo K, Lu J, He B, et al. Polymeric micelles anchored with TAT for delivery of antibiotics across the blood–brain barrier. Biopolymers. 2008;90:617–23.

    Article  PubMed  CAS  Google Scholar 

  149. Fazil M, Md S, Haque S, Kumar M, Baboota S, Sahni JK, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci. 2012;47:6–15.

    Article  PubMed  CAS  Google Scholar 

  150. Ruan Y, Yao L, Zhang B, Zhang S, Guo J. Antinociceptive properties of nasal delivery of neurotoxin-loaded nanoparticles coated with polysorbate-80. Peptides. 2011;32:1526–9.

    Article  PubMed  CAS  Google Scholar 

  151. Ren T, Xu N, Cao C, Yuan W, Yu X, Chen J, et al. Preparation and therapeutic efficacy of polysorbate-80-coated amphotericin B/PLA-b-PEG nanoparticles. J Biomater Sci Polym Ed. 2009;20:1369–80.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS AND DISCLOSURES

This work was supported by the National Basic Research Program of China (973 Program, 2013CB932502), National Science and Technology Major Project (2012ZX09304004) and National Natural Science Foundation of China (81001404).

Author information

Authors and Affiliations

  1. Key Laboratory of Smart Drug Delivery (Fudan University) Ministry of Education; Department of Pharmaceutical Sciences, School of Pharmacy, Fudan University, 826 Zhangheng Road, Shanghai, 201203, China

    Huile Gao, Zhiqing Pang & Xinguo Jiang

Authors
  1. Huile Gao
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhiqing Pang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xinguo Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xinguo Jiang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Gao, H., Pang, Z. & Jiang, X. Targeted Delivery of Nano-Therapeutics for Major Disorders of the Central Nervous System. Pharm Res 30, 2485–2498 (2013). https://doi.org/10.1007/s11095-013-1122-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-013-1122-4

KEY WORDS

Search

Navigation